Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.44 |
| ▸ | KIF11 | P52732 | 4/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1755260 | 0.80 | PDE2A (0.46) | PDE2AKIF11CES2NOTUMTAS2R14 | |
| SCHEMBL1538943 | 0.76 | PDE2A (0.56) | PDE2AKIF11CES2NOTUMPTPN5 | |
| SCHEMBL5841906 | 0.76 | CES2 (0.57) | PDE2AKIF11CES2PTPN5TSHR | |
| SCHEMBL11157398 | 0.74 | PDE2A (0.42) | PDE2AKIF11CES2NOTUMTAS2R14 | |
| SCHEMBL1538689 | 0.74 | CES2 (0.50) | PDE2AKIF11CES2NOTUMTAS2R14 | |
| SCHEMBL1859691 | 0.74 | PDE2A (0.50) | PDE2AKIF11NOTUMTAS2R14PTPN5 | |
| SCHEMBL21131180 | 0.73 | CYP1A2 (0.47) | PDE2AKIF11NOTUMPTPN5RAPGEF4 | |
| SCHEMBL169007 | 0.73 | PDE2A (0.53) | PDE2AKIF11MAPTTSHR | |
| SCHEMBL2267852 | 0.73 | MTOR (0.48) | PDE2AKIF11CES2NOTUMTAS2R14 | |
| SCHEMBL8985702 | 0.73 | HSD17B2 (0.49) | PDE2AKIF11TAS2R14MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009023669-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-02-19 | — | — | WO | claimed |
| US-20090048295-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF | JANSSEN PHARMACEUTICE N.V. (BE) | 2009-02-19 | — | — | US | claimed |
| WO-2009023669-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048295-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF | JANSSEN PHARMACEUTICE N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048295-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF | C3AR1, C5AR1, C5AR2 | PDE2A 687/4885KIF11 4884/4885CES2 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.